RT Journal Article
SR Electronic
T1 Strategic anti-SARS-CoV-2 serology testing in a low prevalence pandemic: The COVID-19 Contact (CoCo) Study in health care professionals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.06.20169250
DO 10.1101/2020.08.06.20169250
A1 Georg Behrens
A1 Anne Cossmann
A1 Metodi V. Stankov
A1 Bianca Schulte
A1 Hendrik Streeck
A1 Reinhold Förster
A1 Berislav Bosnjak
A1 Stefanie Willenzon
A1 Anna-Lena Boeck
A1 Anh Thu Tran
A1 Thea Thiele
A1 Theresa Graalmann
A1 Moritz Z. Kayser
A1 Anna Zychlinsky Scharff
A1 Christian Dopfer
A1 Alexander Horke
A1 Isabell Pink
A1 Torsten Witte
A1 Martin Wetzke
A1 Diana Ernst
A1 Alexandra Jablonka
A1 Christine Happle
YR 2020
UL http://medrxiv.org/content/early/2020/08/07/2020.08.06.20169250.abstract
AB Background Serology testing is explored for epidemiological research and to inform individuals after suspected infection. During the COVID-19 pandemic, frontline healthcare professionals (HCP) may be at particular risk for infection. No longitudinal data on functional seroconversion in HCP in regions with low COVID-19 prevalence and low pre-test probability exist.Methods In a large German university hospital, we performed weekly questionnaire assessments and anti-SARS-CoV-2 IgG measurements with various commercial tests, a novel surrogate virus neutralization test, and a neutralization assay using live SARS-CoV-2.Results From baseline to week six, n=1,080 screening measurements for anti-SARS CoV-2 (S1) IgG from n=217 frontline HCP (65% female) were performed. Overall, 75.6% of HCP reported at least one symptom of respiratory infection. Self-perceived infection probability declined over time (from mean 20.1% at baseline to 12·4 % in week six, p<0.001). In sera of convalescent PCR-confirmed COVID-19 patients, we measured high anti-SARS-CoV-2 IgG levels, obtained highly concordant results from ELISAs using e.g. the S1 spike protein domain and the nucleocapsid protein (NCP) as targets, and confirmed antiviral neutralization. However, in HCP the cumulative incidence for anti-SARS-CoV-2 (S1) IgG was 1.86% for positive and 0.93% for equivocal positive results over the six week study period. Except for one HCP, none of the eight initial positive results were confirmed by alternative serology tests or showed in vitro neutralization against live SARS CoV-2. The only true seroconversion occurred without symptoms and mounted strong functional humoral immunity. Thus, the confirmed cumulative incidence for neutralizing anti-SARS-CoV-2 IgG was 0.47%.Conclusion When assessing anti-SARS-CoV-2 immune status in individuals with low pre-test probability, we suggest confirming positive results from single measurements by alternative serology tests or functional assays. Our data highlight the need for a methodical serology screening approach in regions with low SARS-CoV-2 infection rates.Competing Interest StatementAJ reports grants and personal fees from Novartis, grants and personal fees from Abbvie, grants and personal fees from Gilead, personal fees from Roche, outside the submitted work; TW reports grants and personal fees from Novartis, grants and personal fees from Abbvie, personal fees from Gilead, personal fees from Chugai, personal fees from Sanofi-Aventis, non-financial support from Aesku.Diagnostics, outside the submitted work; DE reports grants and personal fees from Novartis, grants and personal fees from Abbvie, grants and personal fees from Gilead, personal fees from Sanofi Aventis, personal fees from GSK, outside the submitted work; IP reports personal fees from Chiesi and personal fees from Boehringer Ingelheim, outside the submitted work; GB reports grants and personal fees from Gilead, and personal fees from ViiV Healthcare, MSD, and Janssen outside the submitted work; Other authors have nothing to disclose.Clinical TrialGerman Clinical Trial Register (DRKS00021152)Funding Statement. This study is supported by an unrestricted grant from Novartis to GMNB, AJ, DE, CH, from PARI to CH, AJ, CD, MW, and Verein Kinderherz Hannover. GMNB, MW and AJ are supported by the German Centre for Infection Research (DZIF). RF is supported by Deutsche Forschungsgemeinschaft, DFG Excellence Strategy EXC 2155 RESIST project number 39087428, Sonderforschungsbereich SFB900 project number 158989968 - SFB 900 and by a fund of the state of Lower Saxony (14 - 76103-184 CORONA-11/20). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The here presented analyses were approved by local authorities (Data Security Management and Institutional Review Board of Hannover Medical School), approval number 8973_BO_K_2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.